Cambridge Healthtech Institute’s 2nd Annual

Optimizing Drug Metabolism & Pharmacokinetics

Innovative Tools and Strategies for Lead Optimization and Early Dosing

June 18-19, 2019

Lead compounds in drug discovery need to be optimized for both efficacy and safety. Unfortunately, some of the adverse events related to drug metabolism, transport, drug-drug interactions and drug clearance do not surface until much later in development. Improvements in cell-based assays, new predictive models for in vitro and in silico testing, and the emphasis on fail fast, fail early has driven the need for more efficient and effective PKPD and ADME testing. Cambridge Healthtech Institute’s conference on Optimizing Drug Metabolism & Pharmacokinetics will bring together experts from discovery chemistry, ADME, DMPK, and PKPD groups to talk about some of the drug metabolism issues that are important, from lead optimization to early dosing in humans. The talks and discussions will cover what’s new and relevant in ADME and PKPD assessments using relevant case studies, research findings, and highlighting use of innovative assays and technologies.


Structural Attributes Influencing Unbound Tissue Distribution

Li Di, PhD, Research Fellow, Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc.

Intracellular Pharmacokinetics (ICPK): An Emerging Area in Drug Discovery and Development

Andreas Reichel, PhD, Head of Research Pharmacokinetics, Bayer AG

Intestinal Excretion is Becoming an Important Attribute for Drug Discovery

Donglu Zhang, PhD, Senior Scientist, Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc.


Application of Mechanistic PKPD Models in Preclinical to Clinical Translation of Biotherapeutics

Alison Betts, PhD, Associate Research Fellow, Translational Modeling & Simulation, Biomedicine Design, Pfizer Worldwide R&D

Molecular Modeling and Data Mining in Biotransformation for Metabolism-Directed Lead Optimization

Hao Sun, PhD, Principal Pharmacokineticist, DMPK, Seattle Genetics


High-Throughput and Ultra High-Throughput Mass Spectrometry for HT-ADME Support

Wilson Shou, PhD, Senior Principal Scientist, Discovery Chemistry Platforms, Bristol-Myers Squibb Co.

Quantitative Analysis of Major Biotransformation on Antibody-Drug Conjugates

Cong Wei, PhD, Senior Scientist and Group Leader, Vertex Pharmaceuticals

High Content Metabolic Stability in Drug Discovery

Maria Fitzgerald, Scientific Director, DMPK, Sanofi

PANEL DISCUSSION: Challenges Associated with Performing HT-ADME Studies

This panel will bring together session speakers and 2-3 technical experts from leading technology and service companies to discuss improvements and limitations in assays, platforms, and data analysis tools available for ADME and DMPK studies.

Moderator: Wilson Shou, PhD, Senior Principal Scientist, Discovery Chemistry Platforms, Bristol-Myers Squibb Co.

For more details on the conference, please contact:
Tanuja Koppal, PhD
Conference Director
Cambridge Healthtech Institute

For partnering and sponsorship information, please contact:

Companies A-K
Rod Eymael
Business Development Manager
Cambridge Healthtech Institute
Phone: 781-247-6286

Companies L-Z
Joseph Vacca, M.S.
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5431